Genprex Inc Stock Price, News & Analysis

Genprex, Inc. (NASDAQ: GNPX) has announced that its President and CEO, Rodney Varner, will participate in a webinar series with CEO Roadshow to present a company overview to investors each month from July to September 2021. Key dates include July 21, August 18, and September 22. The webinars will include a Q&A session and will be available for replay. Genprex focuses on developing gene therapies for cancer and diabetes, with its lead product, REQORSA™, undergoing evaluation for non-small cell lung cancer.

Genprex, Inc. (GNPX) announced FDA confirmation that all comments regarding its Acclaim-1 clinical trial protocol have been addressed. This Phase 1/2 trial evaluates REQORSA™ Immunogene Therapy combined with AstraZeneca's Tagrisso® for late-stage non-small cell lung cancer patients who have progressed after Tagrisso treatment. Genprex has engaged its first clinical site and aims to enroll 18 patients in Phase 1 and 74 in Phase 2. The trial’s primary endpoint is progression-free survival, with an interim analysis planned at 51 events.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, is participating in Noble Capital Markets' Virtual Roadshow on May 20, 2021. The event features a corporate presentation by President and CEO Rodney Varner and a Q&A session with analyst Robert LeBoyer. Registration is free for all investors. Genprex focuses on developing innovative therapies for cancer and diabetes, with its lead candidate, REQORSA™, targeting non-small cell lung cancer (NSCLC) and having received FDA Fast Track Designation. More information is available on their official website.

Genprex, Inc. (NASDAQ: GNPX), a gene therapy company focused on cancer and diabetes treatments, has announced its participation in several investor conferences throughout May. Presentations will be led by President and CEO Rodney Varner.

Key Events:

• Diamond Equity Emerging Growth Invitational: May 11, 11-11:25 a.m. ET
• Benzinga Small Cap Conference: May 14, 12:45-1:05 p.m. ET
• CEO Roadshow Webinar: Weekly on Thursdays from April 22 to June 10, 11-11:30 a.m. ET

Recordings will be available post-conference on Genprex's website.

Genprex, Inc. (GNPX) announced an amendment to its License Agreement with a major cancer research center in Houston, granting the company an exclusive worldwide license for six patents and one patent application. The Newly Licensed IP aims to enhance treatment for non-small cell lung cancer (NSCLC) by combining TUSC2 therapy with EGFR inhibitors or other therapies. The lead candidate, REQORSA™, has been granted Fast Track Designation by the FDA for NSCLC in conjunction with Tagrisso. Genprex is set to launch Acclaim-1 and Acclaim-2 clinical trials combining REQORSA with other therapies.

Genprex (NASDAQ: GNPX) announced receiving centralized Institutional Review Board (IRB) approval for the Acclaim-1 clinical trial protocol targeting non-small cell lung cancer (NSCLC). This open-label, multi-center Phase 1/2 trial will evaluate the combination of REQORSA™ immunogene therapy and AstraZeneca’s Tagrisso® in late-stage NSCLC patients with mutated EGFRs. With FDA Fast Track Designation already secured, Genprex aims to initiate the trial at 15 U.S. sites, enrolling approximately 92 patients, and an interim analysis will occur after 25 clinical events.

Genprex, Inc. (NASDAQ: GNPX) has initiated the recruitment of clinical trial sites for the Acclaim-2 trial, targeting late-stage non-small cell lung cancer (NSCLC) patients. This Phase 1/2 open-label trial will examine the combination of REQORSA™ immunogene therapy and Merck's Keytruda in patients with low PD-L1 expression. Approximately 150 patients at around 15 sites will be enrolled in this adaptive trial. The protocol may be adjusted based on investigator feedback, aiming to provide new treatment options for NSCLC patients.

Genprex, Inc. (NASDAQ: GNPX) announced its President and CEO, Rodney Varner, will participate in a weekly webinar series hosted by CEO Roadshow from April 22 to June 10, 2021.

The webinars will occur every Thursday from 11-11:30 a.m. EDT, providing an overview of the company and its gene therapy developments for cancer and diabetes. Attendees can ask questions after each presentation, and replays will be available on the company's website. Genprex focuses on innovative therapies, notably its lead candidate REQORSA™ for non-small cell lung cancer.

Genprex, Inc. (NASDAQ: GNPX) has been awarded the inaugural "License of the Year" from the University of Pittsburgh Innovation Institute for its diabetes gene therapy, GPX-002. This therapy aims to convert pancreas alpha cells into insulin-producing beta-like cells, potentially curing diabetes. Preclinical results show promise with mice, indicating blood glucose levels normalized for up to four months. The award recognizes the innovative work of Dr. George Gittes at UPMC, enhancing the company's reputation in gene therapy.